Related Experiment Video

Updated: Mar 31, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.9K

miR-29a suppresses growth and metastasis in papillary thyroid carcinoma by targeting AKT3

Rui Li1, Jia Liu2, Qun Li2

  • 1Institute of Virology and AIDS Research, The First Hospital of Jilin University, Changchun, 130021, China.

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|October 21, 2015
PubMed

Insights

MicroRNA-29a (miR-29a) acts as a tumor suppressor in papillary thyroid carcinoma (PTC). Downregulation of miR-29a promotes PTC growth and metastasis by targeting AKT3, suggesting its potential as an anti-tumor agent.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • MicroRNA-29a (miR-29a) is implicated in various cancers, but its role in papillary thyroid carcinoma (PTC) is not well understood.
  • Understanding miR-29a's function in PTC is crucial for developing new therapeutic strategies.

Purpose of the Study:

  • To investigate the biological function and molecular mechanisms of miR-29a in papillary thyroid carcinoma.
  • To determine if miR-29a can serve as a potential therapeutic target for PTC.

Main Methods:

  • Analysis of miR-29a expression in PTC tissues and correlation with clinicopathological features.
  • In vitro functional assays (cell proliferation, migration, invasion, apoptosis, cell cycle) and in vivo xenograft mouse models.
  • Luciferase reporter assays to identify miR-29a targets, including AKT3, and investigation of the PI3K/AKT pathway.

Main Results:

  • miR-29a was significantly downregulated in PTC tissues and associated with tumor size, TNM stage, and lymph node metastasis.
  • Overexpression of miR-29a suppressed PTC cell proliferation, migration, and invasion, induced apoptosis, and caused cell cycle arrest.
  • miR-29a directly targets AKT3, inhibiting the PI3K/AKT pathway; AKT3 was upregulated in PTC and inversely correlated with miR-29a levels.

Conclusions:

  • miR-29a functions as a tumor suppressor in PTC by targeting AKT3 and inhibiting the PI3K/AKT pathway.
  • Restoration of miR-29a expression may represent a novel therapeutic approach for papillary thyroid carcinoma treatment.
Keywords:
AKT3Papillary thyroid carcinomaProliferationmiR-29a

More Related Videos

Spontaneous Murine Model of Anaplastic Thyroid Cancer05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.4K
An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

21.8K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K